Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telmisartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 6/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telmisartan SCHEMBL29356790 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29691699 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL2122886 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL4464 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL1071821 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL3384004 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL998659 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29032036 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL972356 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29113697 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054198-A1 | REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | WO | claimed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | claimed |
| CN-122036588-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in indole mother nucleus drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036574-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in modification of terminal carboxylic acid drug | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036573-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in diclofenac-like drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12605366-B2 | Telmisartan for the treatment of hypertension in dogs | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260035447-A1 | METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION | SCHOLAR ROCK INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12491177-B2 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | GENVARA BIOPHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3996705-A1 | TELMISARTAN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE IN DOGS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| EP-3996709-A1 | TELMISARTAN FOR THE TREATMENT OF HYPERTENSION IN DOGS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022097090-A1 | DOSING REGIMEN FOR COMBINATION THERAPIES WITH MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND GAMMA SECRETASE INHIBITORS | NOVARTIS AG (CH) | 2022-05-12 | — | — | WO | disclosed |
| CN-114450004-A | Telmisartan for the treatment of chronic kidney disease in dogs | 勃林格殷格翰动物保健有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3982961-A1 | TREATMENTS OF ANGIOEDEMA | Kalvista Pharmaceuticals Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| CN-105164261-B | Compounds and methods for enhanced cellular uptake | 莱古路斯治疗法股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220079926-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CENTAURUS THERAPEUTICS | 2022-03-17 | — | — | US | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-1863458-B2 | SOLVENT SYSTEM FOR ENHANCING THE SOLUBILITY OF PHARMACEUTICAL AGENTS | PATHEON SOFTGELS INC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | CD44, FUT6, MSN | AGTR1 2514/4885PPARG 4317/4885AGTR2 2851/4885 |
| US-20220079926-A1 | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE | CERS2, DEGS1, SMPD1 | AGTR1 2412/4885PPARG 1175/4885AGTR2 3183/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | AGTR1 990/4885PPARG 836/4885AGTR2 835/4885 |
| US-12605366-B2 | Telmisartan for the treatment of hypertension in dogs | REN, TSHR, TRHR | AGTR1 30/4885PPARG 1884/4885AGTR2 44/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | AGTR1 2377/4885PPARG 30/4885AGTR2 2727/4885 |
| US-20260035447-A1 | METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION | MYLK2, CKMT1A; CKMT1B, MYOF | AGTR1 2827/4885PPARG 1188/4885AGTR2 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.